Clinical trials: Epithelial Neoplasms, Malignant
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Barrett Esophagus, Esophageal Cancer
EsophaCap for the Detection of Early Esophageal Carcinoma
This study is to identify potential biomarkers for the early detection of Barrett's Esophagus, esophageal carcinoma (both adenocarcinoma and squamous cell carcinoma), and gastric cancer via sponge cytology.
- Conditions
- Barrett Esophagus, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT04214119
- Where
- 2 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Medulloblastoma
Study of Tomotherapy HD in Medulloblastoma
The aim of the study was to improve local control and long-term survival in children with medulloblastoma, reduce the side effects of treatment and improve quality of life.
- Trial name
- NCT03675230
- Testing
- Tomotherapy HD, 3DCRT
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors
Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.
This study is a prospective, randomized, parallel-controlled clinical trial, with the primary objective to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to…
- Trial name
- NCT06772428
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Atezolizumab plus bevacizumab is the first-line treatment for patients with advanced hepatocellular carcinoma. However, the prognosis for high-risk hepatocellular carcinoma is still poor, with a median overall survival of 7.6…
- Trial name
- NCT05886465
- Testing
- Atezolizumab, Bevacizumab, HAIC with FOLFOX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery…
- Trial name
- NCT00198367
- Testing
- Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Stage IV Lung Adenocarcinoma
Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
The purpose of this study is to test the safety of certolizumab when it is given with the chemotherapy drugs cisplatin and pemetrexed. Cisplatin and pemetrexed are two chemotherapy drugs used in the treatment of lung cancer.
- Trial name
- NCT02120807
- Testing
- Certolizumab, cisplatin, pemetrexed
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary Bladder Neoplasms
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC.
- Trial name
- NCT04109092
- Testing
- E7766
- Where
- 9 sites in United States
- Sponsor
- Eisai Inc.
Neoplasms, Solid Tumors
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2…
- Conditions
- Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm
- Trial name
- NCT07631871
- Testing
- Zanidatamab
- Volunteers
- 10 people
- Sponsor
- Haihua Yuan
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Malignant Glioma, Myelosuppression
Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
This research trial studies an adherence monitoring system in managing myelosuppression in patients with newly diagnosed malignant gliomas who are receiving temozolomide and radiation therapy.
- Trial name
- NCT02375334
- Testing
- Medical Chart Review
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Carcinoma
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.
- Trial name
- NCT05634564
- Testing
- Tislelizumab, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 62 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to look at how patients respond to treatment with guadecitabine and pembrolizumab. The researchers will also be looking at the amount of time it takes for cancer to get worse when participants take…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02901899
- Testing
- Guadecitabine, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Northwestern University
Ovarian Cancer, Breast Cancer
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced…
- Conditions
- Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
- Trial name
- LNCB74-01 (NCT06774963)
- Testing
- LNCB74
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- LigaChem Biosciences, Inc.
Hematuria, Urothelial Carcinoma
Urine DNA Methylation Detection for Hematuria Evaluation
Background: Hematuria, a common symptom of urinary system diseases, can result from various causes including infection, stones, trauma, and tumors.
- Conditions
- Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT06427993
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Changhai Hospital
Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor…
- Conditions
- Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
- Trial name
- NCT07554521
- Testing
- Tislelizumab, Capecitabine, 5-fluorouracil (5-FU)
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Mammary Ductal Carcinoma
The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer
The purpose of this study is to determine how MRI changes the treatment and diagnostics of ductal breast cancer. 100 women with newly diagnosed breast cancer will participate the study.
- Trial name
- NCT01484704
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Atypical Ductal Hyperplasia
Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
This research study is studying whether contrast enhanced mammography can predict if atypical ductal hyperplasia will progress to cancer. The device involved in this study is: -Contrast enhanced mammography
- Trial name
- NCT03505372
- Testing
- Contrast enhanced mammography
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
This study is a prospective, open-label, multi-center phase III study; patients with untreated stage IIIA to stage IVB head and neck squamous cell carcinoma (including oral cavity cancer, oropharyngeal cancer, hypopharyngeal…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
- Trial name
- NCT06102395
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Beijing Tongren Hospital
Lung Cancer, Metastatic Cancer
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment for primary lung cancer or lung metastases that cannot be removed by surgery.
- Trial name
- NCT00303901
- Testing
- cryosurgery, positron emission tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.